Li and co‐workers developed a TME‐activatable prodrug vesicle by encapsulating the OXA prodrug and PEGylated PS into a single nanomedicine for cancer chemo‐immunotherapy.[148] The developed nanomedicine responded to a weak acid, MMP‐2, and GSH, leading to tumor‐specific accumulation, activation, and deep penetration. This evidence concerns the gene MMP2 and neoplasm.